menu
    • menu

    Company profile for Celularity

    NEW Drugs in Dev: 11
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease. Our other products seek to augment longevity by targeting organ a...
    Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease. Our other products seek to augment longevity by targeting organ and tissue repair and functional regeneration. With this approach, our ambition is to augment human immunity and longevity, and to improve the human health span.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CelularityUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    33 Technology Drive Warren, NJ 07059
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://celularity.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Celularity Files 10-K, Regains Nasdaq Compliance
    Celularity Files 10-K, Regains Nasdaq Compliance

    01 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7259570

    FIRSTWORD PHARMA
    01 May 2026
    Share Share
    Celularity Announces Closing of Transaction with NexGel
    Celularity Announces Closing of Transaction with NexGel

    21 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/21/3277939/0/en/celularity-announces-closing-of-transaction-with-nexgel.html

    GLOBENEWSWIRE
    21 Apr 2026
    Share Share
    Celularity Receives Nasdaq Notice For Late Form 10-K Filing
    Celularity Receives Nasdaq Notice For Late Form 10-K Filing

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7187988

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share
    NEXGEL Reschedules Shareholder Call For Celularity Transaction
    NEXGEL Reschedules Shareholder Call For Celularity Transaction

    17 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/17/3276466/0/en/NEXGEL-Moves-Forward-Shareholder-Update-Call-to-Discuss-Celularity-Transaction-on-April-21st-at-4-30-P-M-ET.html

    GLOBENEWSWIRE
    17 Apr 2026
    Share Share
    Celularity Renews NEXGEL Partnership For Biomaterials Franchise
    Celularity Renews NEXGEL Partnership For Biomaterials Franchise

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254647/0/en/Celularity-Reiterates-Strategic-Commercialization-Partnership-with-NEXGEL-Focused-on-Building-Biomaterials-Franchise-with-Established-Commercial-Products-and-New-510-k-Pathway-Prod.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    Celularity Secures $35M License Deal To Boost Longevity Strategy
    Celularity Secures $35M License Deal To Boost Longevity Strategy

    10 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/10/3252827/0/en/Celularity-Secures-35-Million-Strategic-License-Deal-Strengthens-Capital-Position-to-Advance-Longevity-Focused-Strategy.html

    GLOBENEWSWIRE
    10 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search